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Affinity labelhng experiments with different azido- iz51-apamin derivatives were carried out to identify polypeptide compo- 
nents of the apamin-sensitive Ca*+ -activated Kf channel in brain and pheochromocytoma cell membranes. Different 
polypeptides were labelled with different apamin derivatives. The major component has a molecular mass of about 30 
kDa but other components at 45, 58 and 86 kDa were also identified. Results obtained with brain membranes on one 
hand and pheochromocytoma cells on the other were not exactly identical and suggest hat there are sub-types of apamin 
receptors. 
Apamin; Ca2+-activated K+ channel 
1. INTRODUCTION 
Apamin is a bee venom neurotoxin of 18 amino 
acids [l] that blocks with a high affinity a class of 
Ca’+-sensitive K+ channels [2,3]. This Ca’+- 
activated K+ channel is responsible for the after- 
hyperpolarization observed in a number of ex- 
citable cells [4-71 and is known to have a small 
conductance [4,8]. 
Although extensive information is available con- 
cerning the localization of apamin receptors (i.e. 
putative apamin-sensitive Ca’+-activated K+ chan- 
nels) in the brain [9, lo], the exact subunit structure 
of the toxin-binding-site component is not yet 
known. The total molecular mass of the receptor 
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protein has been found to be 250 kDa by radiation 
inactivation techniques [l l] and 350 kDa by 
sucrose gradient centrifugation [12]. A first series 
of affinity labelling experiments with DSS has 
identified a polypeptide at -30 kDa [11,13], 
however other authors have later identified 
polypeptides of 44 kDa, 59 kDa and 86 kDa 
[14,15]. 
In order to resolve these apparent discrepancies 
and to definitely identify polypeptides involved 
in the formation of the apamin-sensitive 
Ca2+-activated K+ channel, we have in this work 
used (i) 2 types of membrane preparations, one 
from rat brain and one from PC12 cells which have 
been shown to overexpress the apamin receptor 
[16], and (ii) 6 different ways to graft the toxin to 
its protein receptor. 
2. MATERIALS AND METHODS 
Apamin was radioiodinated according to Hugues et al. 1171 
except that ‘251-monoiodoapamin was purified by high- 
performance liquid chromatography (HPLC) using a TSK 
SP-5PW column (0.75 x 7.5 cm). Monoiodoapamin was eluted 
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with a linear 0 to 400 mM NaCl gradient (eluent B) in 50 mM 
phosphate buffer, pH 6, with a slope of 2% B per min and a 
flow rate of 1 ml/min. HPLC purified “~1-monoiodoapamin 
was eluted at 230 mM NaCl. Under these conditions ‘?- 
monoiodoapamin was completely devoid of any contamination 
by native apamin. 
Photoreactive ‘251-monoiodoapamin with a specific radioac- 
tivity of 2000 Ci/mmol was prepared as described by Seagar et 
al. [14] except that the incubation was performed in 100 mM 
carbonate buffer at pH 9. 
PC12 cells were grown in H16 medium, supplemented with 
10% horse serum and 5% fetal calf serum, at 37°C and 5% 
COz. After 7 days of culture, cells were scraped off and washed 
with a 10 mM Tris-Cl buffer at pH 7.5, containing a mixture of 
protease inhibitors (1 ,uM pepstatin A, 0.1 mM phenylmethyl- 
sulfonyl fluoride, 1 mM iodoacetamide, 5 mM EDTA). Cells 
were pelleted at 5000 x g, resuspended in the same buffer and 
then homogenized with a Potter homogenizer. Protein concen- 
trations were measured by the Bradford method [18] (Biorad), 
using bovine serum albumin as a standard. Homogenized PC12 
cells were frozen and stored in liquid nitrogen until use. 
Rat brain membranes were prepared with the same mixture 
of protease inhibitors used in PC12 cell preparations. Briefly, 
rats were killed by decapitation, brains were collected and 
homogenized with a Potter homogenizer in ice-cold Tris-Cl 
(20 mM) at pH 7.5, containing 0.32 M sucrose. The 
homogenate was centrifuged at 1500 x g during 7 min. The 
supernatant was collected and centrifuged for 20 min at 20000 
X g. The pellet was collected, resuspended in a 5 mM Tris-Cl 
buffer at pH 7.5 and lysed during 60 min at 4°C. Lysed mem- 
branes were centrifuged for 30 min at 70000 x g. The pellet was 
collected and frozen in liquid nitrogen until use. 
In photolabelling experiments, brain membranes or PC12 cell 
membranes (1 mg/ml of protein) were incubated in a buffer 
containing 100 mM Tris-Cl at pH 8.2, 5 mM KCl, 0.05% 
bovine serum albumin (buffer A), in the presence of the 
appropriate ‘251-apamin derivative at a concentration of 0.3 nM 
(PC12) or 0.1-0.2 nM (brain membranes) in the presence or 
absence of 0.1 PM unlabelled apamin to evaluate the contribu- 
tion of the non-specific labelling component. Incubation was 
carried out in the dark at 4°C for 30 min, membranes were then 
centrifuged at 12000 x g for 15 min. Pellets were resuspended 
in buffer A and irradiated for 3 min with a UV lamp (Philips 
60 W (h = 253 nm)) at a distance of 5 cm. Membranes were 
then centrifuged and washed twice with buffer A. Pellets were 
resuspended in the denaturation buffer containing 50 mM Tris- 
Cl at pH 6.8, 0.6% SDS, 13.5% glycerol with or without 2% 
@-mercaptoethanol and heated 5 min at 100°C before analysis 
by electrophoresis. When DSS was used as a cross-linker 
reagent, and after incubation with apamin, pellets were 
resuspended in 50 mM carbonate buffer, pH 9, and incubated 
with increasing concentrations of DSS (0.01-l mM) for 
30 min. All experiments described above were performed in the 
presence of the protease inhibitor mixture described above. 
Samples obtained from labelling experiments were analysed by 
SDS-gel electrophoresis with an isocratic concentration of 
polyacrylamide (10%) [19] and submitted to autoradiography 
using Kodak XAR films and an intensifying screen. 
Chemicals: HSAB, ANBNOS, SANPAH and DSS were pur- 
chased from Sigma. ANPAA was a gift of Dr Angelides. i2’I- 
Na (IMS 30) was purchased from Amersham. 
3. RESULTS 
The different cross-linking systems used in this 
work are listed in fig.1. Labelling patterns ob- 
tained with brain membranes were different accor- 
ding to the cross-linkers used (fig.2). A protein of 
30 kDa was labelled with all 1251-apamin 
derivatives used and was in 3 out of the 4 condi- 
tions used in fig.2 the most intensely labelled band. 
The most intensely labelled band with the ANPAA 
derivative of apamin was a protein of 86 kDa. In 
addition two proteins of 58 and 45 kDa were also 
labelled by ANPAA and SANPAH derivatives of 
the toxin. Finally a 28 kDa protein was also label- 
led with the HSAB derivative. The same 
autoradiographic pattern was obtained under non- 
reducing conditions (not shown). 
The major protein labelled with PC12 cell 
homogenates and all the apamin derivatives is a 
30 kDa protein under reducing conditions (fig.3, 
lanes l-10). An 86 kDa protein was also labelled 
with ANPAA. Proteins were slightly labelled at 45 
and 58 kDa when using HSAB or SANPAH. As 
previously observed with rat brain membranes, a 
28 kDa protein was detectable in cross-linking ex- 
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Fig.1. Cross-linking reagents used in this work. 
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Fig.2. Affinity labelling of rat brain membranes with different 
apamin derivatives. Lanes: 1,2, ANPAA; 3,4, SANPAH; 5,6, 
ANBNOS; 7,8, HSAB. Lanes 1,3,6,8 correspond to 
experiments carried out in the presence of 0.1 pM. unlabelled 
apamin (non-specific labelling). All results presented here 
correspond to non-reducing conditions. 
periments with the HSAB derivative. Cross-linking 
experiments with DSS and PC12 cell membranes 
gave results similar to those previously described 
for microsomal brain membranes [l 1,131, i.e. a 
single labelled polypeptide at 30 kDa. Under non- 
reducing conditions (fig.3, lanes 11,12) gel patterns 
revealed that the major protein labelled had a 
molecular mass of 25 kDa. However several slight- 
ly labelled proteins were also seen, in particular a 
18 kDa protein. The same pattern was obtained 
with all cross-linking reagents used. 
All labelling patterns corresponded to specific 
labelling since complete protection was observed in 
the presence of an excess of native apamin. Results 
are summarized in table 1. 
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Labelling of the apamin receptor obtained with different cross- 
linker reagents 
Rat brain membranes PC12 cell membranes 
MR: 86 58 45 30 28 86 58 30 28 
ANPAA xx x x x X XX 
SANPAH x x xx X xx 
ANBNOS xx xx 
HSAB xx x xx x 
DSS xx xx 
MR, molecular mass, in kDa, of the protein; xx, intense 
labelling; x, less intense labelling 
4. DISCUSSION 
This paper describes photoaffinity labelling by 
cross-linking rz51-apamin to its receptor using 
several reagents which are different in their struc- 
ture but not in their photoreactive function (except 
for DSS). Polypeptide labelling patterns are dif- 
ferent with the different cross-linking reagents us- 
ed. The shortest reagents used (ANBNOS, HSAB, 
fig. 1) only differ by the position of the nitrene and 
by the presence of a nitro function (ANBNOS) on 
the phenyl group. It seems that these limited dif- 
ferences are sufficient to give a different labelling 
of the apamin receptor in both PC12 and brain 
membranes. ANBNOS only labelled a 30 kDa pro- 
tein while HSAB labelled both 28 and 30 kDa 
proteins. 
Labelling experiments with ANPAA (fig. 1) gave 
Volume 248, number 1,2 
Fig.3. Affinity labelling of PC12 ceil homogenates with different apamin derivatives. Lanes: 1,2, ANBNOS; 3,4,11,12, HSAB; 5.6, 
SANPAH; 7,8, DSS; 9,10, ANPAA. Lanes: l-10, reducing conditions; 11,12, non-reducing conditions. Lanes 2,4,6,8,11, non-specific 
cross-linking in the presence of 0.1 pM apamin. 
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a labelling of 86, 58, 45 and 30 kDa polypeptides 
in brain membranes and of 86 and 30 kDa 
polypeptides in PC12 cells. This reagent only dif- 
fers from ANBNOS and HSAB by the presence of 
a CH2-NH between the activated ester function 
and the phenyl group bearing the photoreactive 
function. SANPAH (fig.l), which is similar to 
ANPAA with respect o its functional group, only 
allows the labelling of the 30 kDa protein and a 
less marked labelling of 45 and 58 kDa proteins. 
SANPAH differs from ANPAA by the number of 
-CH2- (5 instead of 1) between the two reactive 
groups. This difference could be the explanation 
for the absence of labelling of the 86 kDa band. 
Differences in polypeptides identified by affinity 
labelling of a toxin receptor using different cross- 
linkers have already been observed with w- 
conotoxin [20], a polypeptide toxin specific for one 
class of voltage-sensitive Ca2+ channels. 
The situation is different in PC12 cell mem- 
branes. ANBNOS only labels a 30 kDa band while 
HSAB seems to label two minor bands at 58 and 
45 kDa and a double band in the 30 kDa region. 
SANPAH gives a major labelling at 30 kDa and 
the same two minor bands at 58 and 45 kDa. As 
for brain membranes, DSS only cross-links a pro- 
tein at 30 kDa. Surprisingly ANPAA, unlike in 
brain membranes, primarily labels a band at 
30 kDa, the 86 kDa protein being only slightly 
labelled. Under non-reducing conditions, the 
30 kDa protein identified in PC12 cell membranes 
behaves as a 25 kDa protein. Increases in apparent 
molecular mass after reduction have been found 
for several receptors including the p2 adrenergic 
receptor [21], the opioid receptor [22] and the 
neurotensin receptor [23]. This difference in 
molecular mass suggests the presence of in- 
tramolecular disulfide bonds. This difference 
found with PC12 membranes is not observed with 
brain membranes. 
All these results taken together (table 1) strongly 
suggest that, as already indicated before [ 11,131, 
the -30 kDa protein is an important element of the 
apamin receptor. Other subunits at 45, 58 and 
86 kDa, however, are also clearly associated with 
the apamin-sensitive Ca2+-activated K+ channel. 
The difference observed (table 1) between results 
obtained with brain membranes on one hand and 
PC12 cell membranes on the other hand indicate 
that the apamin receptor is similar but not identical 
in the two types of membranes. This view is consis- 
tent with the observation that the & value for the 
apamin-receptor complex is 20 pM in brain mem- 
branes [17] while it is 350 pM in PC12 membranes 
P61. 
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